Related Experiment Videos
[Patient information and conditioning for allogeneic stem cell transplantation]
1Hematologisk seksjon, Rikshospitalet, Oslo.
Nordisk Medicin
|January 1, 1995
Summary
Allogeneic stem cell transplantation offers a cure for specific bone marrow disorders but carries significant risks of fatal complications. Thorough patient education and stringent evaluation are crucial for acceptable risk in this complex treatment.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Context:
- Allogeneic stem cell transplantation (SCT) is a vital curative option for select patients.
- It is primarily used for malignant blood disorders, but also for rare metabolic anomalies.
- The procedure involves significant risks of early and late-onset complications.
Purpose:
- To outline the indications and risks associated with allogeneic SCT.
- To emphasize the importance of patient informed consent and risk-benefit assessment.
- To highlight the need for optimized preconditioning and stringent patient selection.
Summary:
- Allogeneic SCT can cure life-threatening bone marrow disorders and some metabolic conditions.
- Insufficient preconditioning may fail to eradicate malignant tissue, leading to relapse.
- Serious, potentially fatal, extramedullary side effects can occur, necessitating careful patient management.
Impact:
- Informed consent and rigorous evaluation are paramount for patient safety.
- Restrictive indications and stringent contraindication assessment are vital.
- Optimizing SCT protocols can improve outcomes and mitigate risks for patients.